Home › Companies › Sangamo Therapeutics, Inc. › 2024-2025
At Sangamo Therapeutics, Inc.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 96 asset managers reported how they voted on 12 ballot items in their SEC Form N-PX filings, covering 600 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, OR NEOS, AS… — FOR was 59% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Sangamo Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Sangamo Therapeutics, Inc.’s Form 8-K, filed June 16, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 12, 2025: 12 items on Sangamo Therapeutics, Inc.’s Form 8-K, filed June 16, 2025: 9 elected · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore Sangamo Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Sangamo Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Courtney Beers, Ph.D. | 34,998,605 | 20,276,585 | 1,980,825 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: Robert F. Carey | 34,798,438 | 20,478,896 | 1,978,681 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: Kenneth J. Hillan, M.B., Ch.B. | 33,103,184 | 22,215,859 | 1,936,972 | -- | 82,191,793 | 60% | Elected | — |
| Elect Director: Margaret A. Horn, J.D. | 35,042,472 | 20,305,688 | 1,907,855 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D. | 34,648,234 | 21,461,068 | 1,146,713 | -- | 82,191,793 | 62% | Elected | — |
| Elect Director: John H. Markels, Ph.D. | 35,073,968 | 20,222,255 | 1,959,792 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: James R. Meyers | 34,977,952 | 20,307,696 | 1,970,367 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: H. Stewart Parker | 34,697,484 | 20,766,812 | 1,791,719 | -- | 82,191,793 | 63% | Elected | — |
| Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. | 35,184,523 | 20,124,395 | 1,947,097 | -- | 82,191,793 | 64% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement | 32,804,256 | 23,176,425 | 1,275,334 | -- | 82,191,793 | 59% | Not verified | — |
| 3. Approval of the Amended 2018 Plan | 32,399,878 | 24,199,905 | 656,232 | -- | 82,191,793 | 57% | Not verified | — |
| 4. Ratification of Appointment of Independent Registered Public Accounting Firm | 119,619,742 | 12,041,357 | 7,786,709 | -- | -- | 91% | Not verified | — |
Source: Sangamo Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2025 — read the filing on EDGAR.
Each item below shows how the 96 asset managers that disclosed a Sangamo Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
62% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Alexander D. Macrae, M.B., Ch.B., Ph.D.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.”): 34,648,234 for, 21,461,068 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 62% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Courtney Beers, Ph.D.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Courtney Beers, Ph.D.”): 34,998,605 for, 20,276,585 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: H. Stewart Parker
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: H. Stewart Parker”): 34,697,484 for, 20,766,812 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,135,633 for, 22,900 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 22,900 | 0 | 0 | Against |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: James R. Meyers
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: James R. Meyers”): 34,977,952 for, 20,307,696 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: John H. Markels, Ph.D.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: John H. Markels, Ph.D.”): 35,073,968 for, 20,222,255 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Karen L. Smith, M.D., Ph.D., M.B.A, L.L.M.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.”): 35,184,523 for, 20,124,395 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
60% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Kenneth J. Hillan, M.B., Ch.B.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Kenneth J. Hillan, M.B., Ch.B.”): 33,103,184 for, 22,215,859 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 60% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Margaret A. Horn, J.D.
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Margaret A. Horn, J.D.”): 35,042,472 for, 20,305,688 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2026 and until their successors are duly elected and qualified: Robert F. Carey
Sangamo Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert F. Carey”): 34,798,438 for, 20,478,896 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
57% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 14,000,000 shares; and
Sangamo Therapeutics, Inc.’s own tally for this item (“3. Approval of the Amended 2018 Plan”): 32,399,878 for, 24,199,905 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 8,157,593 for, 1,310 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 0 | 940 | 0 | 0 | Against |
| New Harbor Financial Group, LLC | 0 | 300 | 0 | 0 | Against |
| Jackson National | 105 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 0 | 70 | 0 | 0 | Against |
Combines 6 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, OR NEOS, AS DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT.
Sangamo Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement”): 32,804,256 for, 23,176,425 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 59% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Fund voting reports, all 19 managers: 8,158,533 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 5,999,725 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 1,850,000 | 0 | 0 | 0 | For |
| BlackRock | 1,236,642 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,005,873 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 739,087 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 400,000 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Invesco | 259,602 | 0 | 0 | 0 | For |
| Renaissance | 182,084 | 0 | 0 | 0 | For |
| Northern Trust | 171,030 | 0 | 0 | 0 | For |
| State Street | 145,028 | 0 | 0 | 0 | For |
| Mitsubishi UFJ Asset Management Co., Ltd. | 138,920 | 0 | 0 | 0 | For |
| Citadel | 110,503 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 109,950 | 0 | 0 | 0 | For |
| MERITAGE PORTFOLIO MANAGEMENT | 100,000 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 94,523 | 0 | 0 | 0 | For |
| Fidelity | 65,362 | 0 | 0 | 0 | For |
| CAPSTONE INVESTMENT ADVISORS, LLC | 54,417 | 0 | 0 | 0 | For |
| Dimensional | 43,021 | 0 | 0 | 0 | For |
| Russell Investments | 33,253 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 29,055 | 0 | 0 | 0 | For |
| Vanguard | 27,897 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| BANK OF AMERICA NA | 20,760 | 0 | 0 | 0 | For |
| Woodline Partners LP | 19,240 | 0 | 0 | 0 | For |
Institutional-manager reports, all 85 managers: 13,245,701 for, 666 against, 175,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).
91% Majority: yes · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.
Sangamo Therapeutics, Inc.’s own tally for this item (“4. Ratification of Appointment of Independent Registered Public Accounting Firm”): 119,619,742 for, 12,041,357 against, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 8,158,533 for, 0 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| WASATCH FUNDS TRUST | 4,930,890 | 0 | 0 | 0 | For |
| Vanguard | 1,228,078 | 0 | 0 | 0 | For |
| BlackRock | 618,679 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 400,000 | 0 | 0 | 0 | For |
| Invesco | 259,188 | 0 | 0 | 0 | For |
| Global X | 245,921 | 0 | 0 | 0 | For |
| Charles Schwab | 215,488 | 0 | 0 | 0 | For |
| Fidelity | 157,064 | 0 | 0 | 0 | For |
| State Street | 23,277 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 22,900 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,909 | 0 | 0 | 0 | For |
| Victory Capital | 20,938 | 0 | 0 | 0 | For |
| John Hancock | 3,719 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,283 | 0 | 0 | 0 | For |
| Allianz | 2,916 | 0 | 0 | 0 | For |
| Russell Investments | 1,823 | 0 | 0 | 0 | For |
| Guggenheim | 1,415 | 0 | 0 | 0 | For |
| CITY NATIONAL ROCHDALE FUNDS | 940 | 0 | 0 | 0 | For |
| Jackson National | 105 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 233,166,972 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | WASATCH FUNDS TRUST | 2.11% |
| 2 | Vanguard | 0.53% |
| 3 | BlackRock | 0.27% |
| 4 | Delaware/Macquarie | 0.17% |
| 5 | Invesco | 0.11% |
| 6 | Global X | 0.11% |
| 7 | Charles Schwab | 0.09% |
| 8 | Fidelity | 0.07% |
| 9 | State Street | <0.01% |
| 10 | Blackstone Alternative Investment Funds | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | WASATCH ADVISORS LP | 2.57% |
| 2 | Opaleye Management Inc. | 0.79% |
| 3 | BlackRock | 0.53% |
| 4 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.43% |
| 5 | HighTower Advisors, LLC | 0.32% |
| 6 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 0.17% |
| 7 | Charles Schwab | 0.17% |
| 8 | Invesco | 0.11% |
| 9 | Renaissance | 0.08% |
| 10 | Northern Trust | 0.07% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Armistice Capital, LLC | 17.33% | 13G |
| Vanguard Group | 4.02% | 13F |
| Wasatch Advisors LP | 2.65% | 13G |
| BlackRock | 2.34% | 13F |
| Alexander D. Macrae | 2.00% | DEF14A |
| Renaissance Technologies | 1.36% | 13F |
| Point72 | 1.18% | 13F |
| Geode Capital | 0.98% | 13F |
| Millennium Management | 0.60% | 13F |
| State Street | 0.48% | 13F |
Percentages above are of 233,166,972 shares outstanding, as reported by Sangamo Therapeutics, Inc. on its Form 10-Q dated May 8, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Sangamo Therapeutics, Inc.’s 10-Q dated May 8, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Sangamo Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).
proxyvotesnow.com, “Sangamo Therapeutics (SGMOQ) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/sangamo-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.